Valye reports for unlimited access

Avidia Bancorp, Inc. was incorporated in February 2025 and became the holding company for Avidia Bank following a conversion from mutual to stock form completed in July 2025. The company operates primarily through Avidia Bank, a Massachusetts-chartered stock savings bank headquartered in Hudson, Massachusetts, with nine branch offices serving western Middlesex and eastern Worcester Counties. The bank’s business model centers on deposit-taking and lending activities, including residential mortgages, commercial real estate, commercial and industrial loans, and consumer loans. Additionally, the company provides payments processing services nationwide to small business merchants. The company is regulated by the Federal Reserve Board, Massachusetts Commissioner of Banks, and the FDIC. The market area is part of the Boston and Worcester metropolitan regions, characterized by a populous and economically diverse environment. The company completed a stock offering in 2025, established a charitable foundation and an ESOP, and declared its first quarterly dividend in early 2026. As of June 30, 2026, the company reported net income of $7.17 million and EPS of $0.39 [S1][S2].

Yale Transaction Finders, Inc. operates as a blank check company (special purpose acquisition company) with a business plan to seek, investigate, and potentially acquire one or more businesses or entities through purchase, merger, or similar transactions. The company does not limit its search by geography or industry and focuses on target businesses that desire to become public companies and meet listing requirements for OTC or NASDAQ markets or national stock exchanges. The company has limited financial resources and is unlikely to pursue multiple acquisitions simultaneously. The company’s acquisitions may involve issuance of common stock or other securities, potentially diluting existing shareholders and resulting in changes in control and management. The company’s management and board have discretion to complete acquisitions without shareholder approval, and new management may be appointed post-transaction without shareholder vote. The company’s financial position as of mid-2026 shows a net loss, minimal cash, and a stockholders' deficit.

PAVmed Inc. is a diversified commercial-stage life sciences company operating through subsidiaries in medical devices, diagnostics, and digital health. Its key subsidiaries include Lucid Diagnostics, which markets the EsoGuard Esophageal DNA Test and EsoCheck device for early detection of esophageal precancer and cancer, and Veris Health, a digital health company providing a cancer care platform for continuous patient monitoring. PAVmed also develops medical devices such as the PortIO vascular access device and licensed endoscopic imaging technology. The company pursues commercialization through multiple channels, strategic partnerships, and reimbursement efforts, including a U.S. Department of Veterans Affairs contract for EsoGuard. PAVmed reported a net loss and maintains liquidity with cash and current assets exceeding current liabilities as of mid-2026 [S1][S2].

Constellation Acquisition Corp I operates as a blank check company formed to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company has no operating business and its primary activity is to identify and complete a Business Combination within a specified timeframe. The Sponsor holds a majority of shares and exerts significant control over corporate decisions. The company’s financial position as of mid-2026 shows limited cash resources and a working capital deficit, reflecting the costs incurred in pursuit of a Business Combination. The company’s governance structure allows for amendments to key provisions with shareholder approval, potentially facilitating the completion of a Business Combination even if some shareholders dissent. The company’s warrants are accounted for as derivative liabilities, impacting earnings through fair value adjustments.

DocGo Inc. is a healthcare company focused on transforming care delivery through a vertically integrated platform that combines mobile health services, virtual care management, and ambulance transportation. Operating in all 50 U.S. states and the United Kingdom, DocGo leverages proprietary technology to facilitate efficient, accessible, and patient-centered care outside traditional healthcare facilities. The company’s Mobile Health Services segment addresses care gaps for Medicare and Medicaid populations, while its Transportation Services segment provides medical transport solutions integrated with electronic medical records. DocGo partners with municipalities, hospitals, insurers, and government agencies, serving diverse patient populations and emphasizing early intervention, preventive care, and chronic disease management. The company employs a large clinical and support workforce and invests in comprehensive training and employee engagement programs.

Twelve Seas Investment Co III/Cayman is a special purpose acquisition company (SPAC) incorporated in August 2024 in the Cayman Islands. Its business purpose is to identify and complete a merger, acquisition, or similar business combination with one or more companies, with a focus on international targets, especially in the Pan-Eurasian region and Africa, and sectors such as oil and gas. The company completed its IPO in December 2025, raising $172.5 million, which is held in a trust account. The management team has prior experience with SPACs and international investments. The company has not generated operating revenues and has not yet selected a business combination target. It must complete a business combination by December 15, 2027, or liquidate and return funds to shareholders. The company’s financial position as of June 30, 2026, shows strong liquidity and a net income of $1.4 million, reflecting non-operating income or other gains.

Copley Acquisition Corp operates as a special purpose acquisition company (SPAC) formed to identify and merge with or acquire one or more businesses. The company targets sectors aligned with its management's expertise, specifically enabling technology and lifestyle services. It has a significant trust account balance to fund acquisitions and offers flexibility in structuring deals using equity, debt, or cash. The company has entered into a definitive business combination agreement with Ignite Proteomics, a precision oncology company, subject to customary closing conditions and approvals. The company has no operating revenues to date and reports net income primarily from non-operating sources. It is subject to SEC reporting requirements and has a defined timeline to complete its initial business combination or face liquidation.

Mitesco, Inc. was formed in 2012 and transitioned from healthcare clinic operations to a focus on data center and cloud computing services. Its two main subsidiaries are Centcore, which provides managed data center and cloud hosting services primarily through co-location agreements, and Vero Technology Ventures, which develops AI-based cloud applications and pursues investments in related areas. The company has undergone extensive debt restructuring, converting over $26 million of obligations into equity and preferred stock, and has issued multiple convertible promissory notes secured by its subsidiaries and assets. Mitesco operates with a small team of consultants and directors, without full-time employees, and faces competition from established IT service providers and cloud vendors. It is subject to U.S. regulatory requirements including cybersecurity and data privacy laws.

Charlie's Holdings, Inc. is a company focused on the development, marketing, and sale of nicotine and nicotine alternative products, including vapor products. The company does not have its own manufacturing facilities and relies on third-party contract manufacturers to produce its products. It has submitted Premarket Tobacco Applications (PMTAs) to the FDA for its products, including synthetic nicotine products under the Pacha brand. The company has faced FDA Marketing Denial Orders but has obtained court stays allowing continued marketing of affected products pending litigation. Financially, the company reported revenues of approximately $20.9 million in 2025 but has incurred operating losses and negative cash flows. It faces significant regulatory, competitive, and operational risks, including reliance on key personnel, cybersecurity risks, and the challenges of operating in a highly regulated and evolving market.

BT Brands, Inc. is a multi-concept restaurant operator with nine directly owned restaurants and minority interests in additional locations, spanning fast food, casual dining, seafood, coffee, and fine dining concepts. The company operates under a centralized management platform to leverage efficiencies across its portfolio. Historically focused on food service, BT Brands is undergoing a strategic transformation through a proposed merger with Aero Velocity Inc., a company specializing in unmanned aerial vehicles and drone services. This merger includes a planned spin-off of the restaurant business into a new entity, BT Group, Inc., which will be distributed to existing stockholders. The transaction is complex, involving significant dilution of current shareholders and a shift in control to Aero Velocity investors. BT Brands' financials as of mid-2026 reflect modest revenue and net income, with strong liquidity and capital resources.

ALT5 Sigma Corp is a publicly traded company listed on the Nasdaq Capital Market under the ticker ALTS. It is incorporated in Nevada with principal offices in Las Vegas. The company is classified as a smaller reporting company and files periodic reports with the SEC, including annual and quarterly filings. The latest filings provide detailed financial data including revenue, net income, earnings per share, and liquidity metrics. The company reported a significant net loss in the most recent quarter and has current liabilities exceeding current assets, indicating liquidity challenges. Publicly available information does not disclose detailed business segments or industry classification.

Sandisk Corp is a technology company specializing in computer hardware products. The company has a substantial cash position and current assets exceeding current liabilities, indicating solid liquidity. It operates with a cash conversion cycle of 140 days, reflecting its working capital management. Sandisk has entered into long-term customer agreements resulting in contract liabilities and maintains significant purchase and capital commitments, including those related to Flash Ventures. The company has recently completed early repayment of its term loan facility and initiated a large share repurchase program. Recent earnings reports indicate profitability and revenue growth, particularly driven by datacenter demand.

Greenland Mines Ltd is a biopharmaceutical company developing essential medicines for chronic diseases such as cancer, cardiovascular, and neurodegenerative disorders. The company operates two main platforms: a generic/biosimilar drug portfolio targeting cancer treatments and a proprietary gene therapy platform focused on the Klotho protein for neurodegenerative diseases. The gene therapy platform is based on licensed patents and research from the Autonomous University of Barcelona and other collaborators. The company acquired market-approved anti-cancer drugs in Germany and expanded into critical minerals mining through acquisition of Greenland Mines Corp. The gene therapy candidates, including KLTO-101 for Alzheimer's and KLTO-202 for ALS, are in pre-clinical development. The company is also developing assays to measure Klotho protein isoforms to support therapy development and potential diagnostics. Financially, as of June 30, 2026, Greenland Mines holds $9.3 million in cash with strong liquidity and reported a net loss of $3.685 million for the period.

Clearthink 1 Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in September 2025. Its business model is to identify and complete an initial business combination with a target company, primarily in the financial services sector in developed markets. The company has not yet identified a target or engaged in substantive discussions. It completed its initial public offering in February 2026, raising approximately $125 million, which is held in a trust account. The management team and board have extensive experience in financial services and transactions, aiming to leverage their networks to source acquisition opportunities. The company intends to complete a business combination by November 25, 2027, or else liquidate and return funds to shareholders. The company currently has no operations other than organizational activities and preparation for the business combination.

Skyline Builders Group Holding Ltd is a company that operates primarily in Hong Kong, generating all of its revenue there in recent years. It has some asset presence in Kazakhstan and the United States. The company is engaged in business activities that include construction and recently expanded into mineral property acquisitions in the United States. It has disclosed concentration risks related to customers and subcontractors, and manages credit and liquidity risks through established policies. The company is listed on the Nasdaq Capital Market and adheres to relevant corporate governance and compliance standards.

NexMetals Mining Corp. is a Canadian mining exploration company focused on the exploration and evaluation of copper, nickel, cobalt, and platinum-group elements primarily in Botswana. Its principal assets include the Selebi Main and Selebi North copper-nickel-cobalt mines and the Selkirk mine. The company is in the exploration stage and has not yet generated profitable operations. It is listed on Nasdaq and TSXV under the ticker NEXM. NexMetals has conducted extensive drilling programs with reported significant mineralization intercepts and metallurgical assay results confirming the potential to produce high-grade concentrates. The company has secured title to its key assets following milestone payments and has raised capital through public offerings to fund its exploration and development activities. Recent corporate governance changes include board appointments and a CEO succession plan. The company faces typical exploration-stage risks including the need for additional financing, operational challenges, and commodity price volatility [S1][S2][N1][N2][N3][N4][N6][N7][N8].

ENvue Medical, Inc. develops and commercializes medical devices for enteral feeding, focusing on a navigation-enabled system that assists clinicians in the real-time placement and verification of feeding tubes. The ENvue System is designed to reduce complications associated with traditional blind insertion methods, such as incorrect placement leading to patient harm. The company markets its products primarily in the U.S. acute care hospital sector and sells both the navigation system and proprietary disposable feeding tubes and accessories. ENvue is in the growth stage of commercialization and aims to expand its product portfolio and geographic reach over time. The company was formerly known as NanoVibronix, Inc. and completed a merger in 2025 that led to its current structure and branding [S1].

Gulf Resources, Inc. is a chemical company focused on bromine production and related operations. The company has expanded its production capacity to meet demand and operates through PRC subsidiaries. It maintains compliance with PRC regulations and has not faced significant regulatory sanctions. Gulf Resources has a structured cybersecurity program overseen by its board and has not experienced material cybersecurity incidents recently. The company reported revenues of approximately $25.4 million and a net loss of $43.9 million for the fiscal year ending December 31, 2025. Liquidity metrics indicate a current ratio near 3 and a cash ratio above 1, reflecting adequate short-term liquidity. Recent operational highlights include a 250% sales increase reported in mid-2025 and acquisitions related to salt fields. The company also faced temporary governmental closure of bromine facilities in late 2023.

Lumentum Holdings Inc. designs and manufactures optical components and subsystems primarily for telecommunications, data communications, and industrial applications. The company serves markets including AI infrastructure, data centers, and networking. It operates globally with exposure to Asia, Europe, and North America. Lumentum's business model relies on advanced technology products, a limited number of key suppliers, and significant customer relationships. The company has convertible debt instruments and a revolving credit facility supporting liquidity. Recent operational focus includes ramping AI optics and network product lines.

Reitar Logtech Holdings Ltd is a company engaged in logistics and technology sectors, with recent strategic initiatives including a spin-off of its logistics automation segment and the launch of a new entity focused on food supply chain and smart agriculture solutions. The company has experienced trading interruptions but resumed trading in late 2024. Financial disclosures indicate a net loss and negative earnings per share for the fiscal year ending March 31, 2026, with liquidity ratios slightly below 1, indicating current liabilities slightly exceed current assets.

Dreamland Ltd is an event management service provider incorporated in the Cayman Islands with operations primarily in Hong Kong and Southeast Asia. It specializes in organizing, planning, promoting, and managing themed touring walk-through experience events based on licensed intellectual property from animated and live-action characters. The company also designs and sells merchandise and manages brand-related events such as pop-up stores and product launches. It has nearly a decade of experience and a track record of over 90 projects across multiple territories. The company completed its initial public offering on Nasdaq in July 2025, raising $5.36 million. Its business model includes direct event management and investment deals in experience events, with plans to obtain IP licenses directly to enhance margins and market share.

Bridgeline Digital, Inc. is an AI-powered marketing technology company incorporated in Delaware in 2000, headquartered in Woburn, Massachusetts, with regional offices in the U.S., Canada, and Belgium. The company offers a suite of AI-enhanced software products designed to help businesses grow online revenue by increasing website traffic, improving conversion rates, and raising average order value. Its software is available primarily through a cloud-based SaaS model, with options for perpetual licensing for on-premises or managed hosting deployments. Bridgeline's product portfolio includes AI-powered site search and personalization software such as HawkSearch and Celebros Search, SEO auditing tools like WooRank, digital experience platforms including Unbound and OrchestraCMS, and franchise marketing software TruPresence. The company serves mid-sized and large companies across various verticals including associations, banks, eCommerce retailers, franchises, health services, industrial distribution, manufacturing, and technology. It employs a direct sales force and leverages strategic partnerships with platforms like Adobe, Shopify, and BigCommerce. Bridgeline invests significantly in research and development and maintains a dedicated Customer Success team to support client retention. The company operates in a highly competitive and rapidly evolving market with low barriers to entry and differentiates itself through tailored AI solutions, integrated platforms, flexible deployment options, and complementary development services [S1][S2].

Coeptis Therapeutics Holdings, Inc. underwent a significant business transformation in April 2026, shifting from biopharmaceuticals to crypto asset mining through a merger with Z Squared Inc. The company owns a substantial fleet of ASIC miners and relies exclusively on Minting Dome Inc. for hosting, power, and operational support under a Master Services Agreement that grants Minting Dome broad operational control and limits Coeptis's direct oversight. The company has a new management team with crypto mining experience but limited public company governance experience. Financially, Coeptis reported $1.58 million in revenue and a net loss of $13.79 million for Q2 2026, with strong liquidity metrics. The company has also engaged in strategic transactions and partnerships related to AI and technology integration.

ITHAX Acquisition Corp III is a publicly listed entity with limited publicly disclosed business model details. The company’s latest SEC filings provide financial snapshot data including current assets, liabilities, and net income but do not disclose revenue or segment information. The company’s liquidity position as of mid-2026 appears strong based on reported current assets and liabilities.

Harmonic Inc. is a global provider of broadband access solutions and video delivery software and services. The company operates two segments: Broadband and Video. In June 2026, Harmonic completed the sale of its Video business, shifting its focus entirely to the Broadband segment. The Broadband business offers software-based broadband access solutions, including the cOS™ platform, to broadband operators worldwide. Revenue is generated through appliance and integration sales (hardware, licenses, professional services) and SaaS and service fees, reflecting a mix of non-recurring and recurring revenue streams. The company serves a concentrated customer base, with the top 10 customers accounting for nearly 89% of net revenue in recent periods. Harmonic faces intense competition from larger and better-resourced companies and operates in markets characterized by rapid technological change and pricing pressures. The company’s future growth is linked to broadband industry trends such as increased connected devices, adoption of high-bandwidth technologies, and regulatory developments. Supply chain and geopolitical risks, particularly related to component sourcing and manufacturing, are material considerations.

Cal Redwood Acquisition Corp. is a Cayman Islands exempted blank check company formed in early 2025 to pursue an initial business combination primarily in the technology, media, and telecommunications (TMT) sector and related technology-disrupted industries. The company completed its IPO in May 2025, raising approximately $236.6 million, which is held in a trust account pending a business combination. The management team brings significant operational and investment experience in TMT businesses. As of June 30, 2026, the company has not generated operating revenues and has not selected a specific target business but announced a definitive business combination agreement with Carvix, Inc. The company’s financial position shows a strong liquidity profile with a current ratio of 2.4 and positive net income for the period.

Certiplex Corp is a multimedia company providing business-ready solutions including website and mobile app design, SEO, social media integration, and multimedia content creation. The company also holds licensing rights for the Pro Sun Lighting system, marketed through distribution channels, though no recent licensing revenue has been reported. Revenue is primarily generated from multimedia and website design services. The company has experienced operating losses and a stockholders' deficit, with liquidity ratios indicating significant short-term financial constraints. Management is focused on expanding core services and exploring financing options to support operations.

Estrella Immunopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer immunotherapy drugs. The company is conducting the STARLIGHT-1 Phase I/II clinical trial for its lead candidate EB103 targeting B-cell lymphoma. Estrella is led by CEO Dr. Cheng Liu, an experienced scientist with extensive patents and publications in cancer immunotherapy. The company has a board with diverse expertise and a scientific advisory board with recognized experts. Estrella has engaged in recent financing activities including a $100 million stock and warrants offering and a securities purchase agreement in early 2026. As of mid-2026, the company reported a net loss and limited cash resources, with a current ratio indicating liquidity constraints. The company maintains compliance with Nasdaq listing requirements and holds annual shareholder meetings virtually.

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development of circuit-specific pharmacotherapies for central nervous system disorders. Founded by experts in psychiatry and neuroscience, the company’s lead product candidate, ML-007C-MA, targets muscarinic receptors to treat schizophrenia and Alzheimer's disease psychosis. The company is conducting Phase 2 clinical trials for these indications and has received FDA Fast Track designation for ML-007C-MA in ADP. Since inception, MapLight has focused on research and development, financing operations through equity sales, grants, and public offerings. The company has not generated revenue and reports significant net losses as it advances its clinical pipeline.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company developing cancer immunotherapy and antitumor virotherapy treatments. The company operates subsidiaries in Germany and Australia to support clinical trial activities. Its pipeline includes candidates such as CLD-401 for tumor virotherapy and CLD-201 for solid tumor treatment, with FDA IND clearance and ongoing clinical trials. Calidi has engaged in partnerships to streamline regulatory submissions and clinical trial initiation. The company has raised capital through public offerings and warrant exercises to fund its operations and pipeline development. Calidi is classified as an emerging growth company and smaller reporting company, benefiting from certain reduced reporting requirements. The company has experienced recurring operating losses and negative cash flows, with management noting substantial doubt about its ability to continue as a going concern without additional funding.

Camber Energy, Inc. operates as a diversified technology company focusing on innovative and patented technologies in the energy and environmental sectors. Its portfolio includes a majority interest in Viking Ozone, which owns a patented medical and bio-hazard waste treatment system using ozone technology designed as a sustainable alternative to traditional waste treatment methods. The flagship VKIN-300 unit has achieved significant regulatory progress in France. The company also holds majority interests in entities owning patented electric transmission and distribution broken conductor protection systems aimed at enhancing grid safety and reliability. Additionally, Camber holds an exclusive license for a patented clean energy and carbon-capture system with multiple issued patents and pending applications. The company has a 49% interest in Simson-Maxwell Ltd., a Canadian firm providing custom energy and power solutions including combined heat and power, diesel and natural gas engines, solar, wind, and storage solutions. Following a reduction in ownership and disposal of oil and gas assets, Camber operates as a single reporting segment and currently does not generate revenue. The company relies on outside consultants for operations and has outstanding secured promissory notes and a convertible note. Financially, as of mid-2026, Camber shows liquidity challenges with a current ratio of 0.02 and reported a net loss for the period. The company faces risks related to technology development, financial constraints, and key personnel dependence.

Instil Bio, Inc. is a clinical-stage biotechnology company focused on identifying and advancing innovative therapeutic opportunities, primarily in oncology. The company’s development pipeline included AXN-2510, a bispecific antibody targeting PD-L1 and VEGF family members, which was in-licensed from ImmuneOnco in 2024 but discontinued in early 2026. Prior to AXN-2510, the company developed cell therapies including a proprietary folate receptor alpha CoStAR tumor infiltrating lymphocyte (TIL) therapy. Instil Bio’s strategy centers on acquiring or in-licensing novel therapeutic candidates addressing significant unmet medical needs. The company faces intense competition from larger pharmaceutical and biotechnology firms with greater resources and expertise. Regulatory compliance with FDA and other authorities governs the development, testing, manufacturing, and approval of its product candidates. The company has no approved products and has incurred significant losses since inception. It maintains liquidity through cash, cash equivalents, and marketable securities, with a current ratio indicating strong short-term financial health. The company’s Tarzana, California facility has been impaired and is listed for sale, with AstraZeneca as a lessee and potential purchaser. Instil Bio continues to invest in leadership and development capabilities to advance its pipeline and business objectives.

Contango ORE, Inc. was formed in 2010 to explore and develop gold ore and associated minerals primarily in Alaska. Its core asset is a 30% membership interest in the Peak Gold JV, which leases over 675,000 acres and operates the Manh Choh mines. Kinross Gold Corporation, through its subsidiary KG Mining, holds the remaining 70% interest and manages the JV. Contango also owns several wholly-owned subsidiaries that control mineral rights to other Alaskan properties, including Johnson Tract, Lucky Shot, Eagle/Hona, Triple Z, Shamrock, Willow, Amanita NE, Golden Zone, and Amanita. The company has no proven reserves but holds indicated and inferred resources at some projects. Operations at Peak Gold JV began in mid-2024, generating cash flows and distributions to Contango. The company’s business model depends on exploration success, JV funding, and capital market access.

NMP Acquisition Corp. is a special purpose acquisition company (SPAC) incorporated in the Cayman Islands in December 2024. Its sole business activity since inception has been to raise capital through an IPO and private placements to fund an initial business combination. The company completed its IPO in July 2025, raising gross proceeds of $115 million, which are held in a trust account. The management team, led by CEO Melanie Figueroa and CFO Nadir Ali, has experience in investment banking, financial services, and mergers and acquisitions. The company intends to identify and complete a business combination within 18 months of the IPO, focusing on private companies with resilient business models, industry leadership potential, and growth prospects. The company currently has no revenue and incurs operating costs related to formation and administration. It may use cash, shares, debt, or a combination thereof to complete the business combination. The company’s shares trade on Nasdaq under symbols NMP, NMPAR, and NMPAU for units.

BioAtla, Inc. is a clinical-stage biopharmaceutical company developing a novel class of antibody-based therapeutics called conditionally active biologics (CABs) that target solid tumor cancers. The company leverages proprietary discoveries in tumor biology to enable targeting of tumor antigens that have been difficult to address with prior therapies. BioAtla is listed on the Nasdaq Capital Market under ticker BCAB and is headquartered in San Diego, California. The company has a board of directors with extensive experience in biotechnology, clinical development, and commercial operations. BioAtla's clinical pipeline includes product candidates such as BA3182 and Ozuriftamab Vedotin, with ongoing Phase 1 and Phase 2 clinical trials. The company has secured financing through Pre-Paid Advance Agreements and Standby Equity Purchase Agreements to support its clinical programs. Recent operational actions include workforce reductions and cost-containment measures as part of strategic evaluations. The company is managing liquidity constraints and Nasdaq listing challenges while advancing its clinical pipeline.

VANJIA CORP is a smaller reporting company with limited publicly disclosed information about its business model, industry, or geographic focus. The company has reported no revenue as of mid-2025 and a net loss as of mid-2026. It maintains strong liquidity with a high current ratio and cash ratio based on recent SEC filings. Legal proceedings are ongoing but are not expected by management to materially impact financial condition or operations.